Page 11 - Early Access Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Early access programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Early Access Programs Today - Breaking & Trending Today

Pherecydes Pharma Obtains €2 Million in Non-dilutive Financing From Bpifrance

Pherecydes Pharma Obtains €2 Million in Non-dilutive Financing From Bpifrance
Regulatory News:
Pherecydes Pharma (Paris:ALPHE)
(FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has obtained, within the framework of a State-Guaranteed Loan Innovation Support , a €2 million loan from Bpifrance, the French public investment bank.
This interest-bearing loan benefits from a one-year deferred repayment and Pherecydes Pharma will have the possibility, after the first year, of amortizing the loan over a duration of up to 5 years.
Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, states: ....

Pherecydes Pharma , Philippe Rousseau , Nicolas Merigeau , Dusan Oresansky , Guaranteed Loan Innovation , Charles Fanneau De La Horie , Executive Board , Early Access Programs , French National Agency , பிலிப் ரூஸ்ஸோ , நிர்வாகி பலகை , ஆரம்ப நுழைவு ப்ரோக்ர்யாம்ஸ் ,

Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine) Oral Solution

Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine) Oral Solution
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Melinda Baker , Dan Piggott , Tevard Biosciences , Bradleys Galer , Us Securities Exchange Commission , Zogenix Access Program , European Commission , Uniphar Group Product Access Division , Us Food Drug Administration , Zogenix Launches Global Access Program , Corporate Communications , European Union , European Medicines Agency , Access Program , Oral Solution , Executive Vice President , Chief Medical Officer , Uniphar Group , Product Access Division , Managing Director , Product Access , Risk Evaluation Mitigation Strategy , Controlled Access Program , Drug Administration , Early Access Programs , Named Patient Supply ,

Bionical Emas launches Managed Access Program for JZP 458 - a recombinant Crisantaspase produced in Pseudomonas fluorescens

(0)
WILLINGTON, England, April 8, 2021 /PRNewswire/ Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) following hypersensitivity to E. Coli-derived asparaginases. The Managed Access Program provides a mechanism through which unsolicited physician requests, to fulfil the special need of a patient can be supported.

JZP-458 provides a further therapy option for paediatric and adult patients with ALL or LBL who have not tolerated certain asparaginase treatments and currently have limited treatment options, and we re pleased to support this program, said ....

Tom Watson , Kostenloser Wertpapierhandel , Bionical Emas , John Efthimiou , Prnewswire Bionical Emas , Clinical Research Organization , Jazz Pharmaceuticals , Clinical Development , Access Program , Access Program For Jazz , Managed Access Program , Jazz Pharmaceutical , Acute Lymphoblastic Leukaemia , Lymphoblastic Lymphoma , Chief Medical Officer , Early Access Programs , Clinical Trial , Fast Track , Managed Access , Executive Vice President , Early Access , டோம் வாட்சன் , மருத்துவ ஆராய்ச்சி ஆர்கநைஸேஶந் , ஜாஸ் மருந்துகள் , மருத்துவ வளர்ச்சி , நுழைவு ப்ரோக்ர்யாம் ,

Bionical Emas launches Managed Access Program for JZP 458 - a recombinant Crisantaspase produced in Pseudomonas fluoresc

CET- Comunicado -
;ultimaHoraHtml +=
+ json.lead + ;}ultimaHoraHtml += ;
document.getElementById( urgente ).innerHTML = ultimaHoraHtml;
}
}
});
WILLINGTON, England, April 8, 2021 /PRNewswire/ Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) following hypersensitivity to E. Coli-derived asparaginases. The Managed Access Program provides a mechanism through which unsolicited physician requests, to fulfil the special need of a patient can be supported.
JZP 458 provides a further therapy option for paediatric and adult patients with ALL or LBL who have not tolerated certain asparaginase treatments and currently have limited treatment options, and we re pleased to ....

Tom Watson , Bionical Emas , John Efthimiou , Prnewswire Bionical Emas , Clinical Research Organization , Jazz Pharmaceuticals , Clinical Development , Access Program , Access Program For Jazz , Managed Access Program , Jazz Pharmaceutical , Acute Lymphoblastic Leukaemia , Lymphoblastic Lymphoma , Chief Medical Officer , Early Access Programs , Clinical Trial , Fast Track , Managed Access , Executive Vice President , Early Access , டோம் வாட்சன் , மருத்துவ ஆராய்ச்சி ஆர்கநைஸேஶந் , ஜாஸ் மருந்துகள் , மருத்துவ வளர்ச்சி , நுழைவு ப்ரோக்ர்யாம் , நுழைவு ப்ரோக்ர்யாம் க்கு ஜாஸ் ,